Michael A. Crary, Ph.D., CCC-SLP, FASHA, Author at Dysphagia Cafe

2 POSTS 0 COMMENTS

Michael A. Crary, PhD, FASHA is a professor of Speech-Language Pathology and Co-Director of the Swallowing Research Laboratory at the University of Central Florida in Orlando. He joined the faculty at UCF in August, 2015 as a Provost Scholar.

Aphasia to dysphagia: A challenge to all future SLPs

Michael A. Crary, Ph.D., CCC-SLP, FASHA - April 17, 2017

Crossfit and dysphagia and MDTP and rehabilitation

McNeill Dysphagia Therapy Program – 10 years of research experience with...

Michael A. Crary, Ph.D., CCC-SLP, FASHA - November 19, 2015

Scroll for Important Safety Information

INDICATIONS AND USAGE:

VARIBAR ® THIN HONEY (barium sulfate) oral suspension, VARIBAR ® NECTAR (barium sulfate) oral suspension, and VARIBAR ® THIN LIQUID (barium sulfate) for oral suspension, are indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. VARIBAR ® HONEY (barium sulfate) oral suspension and VARIBAR ® PUDDING (barium sulfate) oral paste are indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients 6 months of age and older.

IMPORTANT SAFETY INFORMATION:
For Oral Administration. This product should not be used in patients with known or suspected perforation of the GI tract, known obstruction of the GI tract, high risk of aspiration, or hypersensitivity to barium sulfate products. Rarely, severe allergic reactions of anaphylactoid nature have been reported following administration of barium sulfate contrast agents. Aspiration may occur during the modified barium swallow examination, monitor the patient for aspiration.

Please consult full Prescribing Information for VARIBAR products by clicking HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit FDA or call 1-800-FDA-1088.